Company Overview and News


Add 531349
to your dashboard

Headline News

Panacea Biotec Limited - Credit Rating

2017-12-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

Panacea Biotec Limited - News Verification

2017-12-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

USFDA accepts Panacea Biotec's ANDA for generic cancer drug

2017-11-30 business-standard
Panacea Biotec today said the US health regulator has accepted its filing for approval of generic version of cancer treatment injection Abraxane. The company's abbreviated new drug application (ANDA) for Paclitaxel Protein bound particles for injectable suspension, 100mg/vial has been accepted for filing by the US Food and Drug Administration (USFDA), Panacea Biotec said in a BSE filing.

USFDA accepts Panacea Biotech’s ANDA for breast cancer drug

2017-11-30 livemint
New Delhi: Drug firm Panacea Biotech on Thursday confirmed that the US Food and Drug Administration (FDA) has accepted its abbreviated new drug application (ANDA) to evaluate its dossier for marketing paclitaxel protein-bound particles for injectable suspension (100 mg per vial) in the US.

Panacea Biotec gets USFDA nod to file for generic cancer drug

2017-11-30 moneycontrol
Panacea Biotec today said the US health regulator has accepted its filing for approval of generic version of cancer treatment injection Abraxane.

USFDA accepts Panacea Biotec's ANDA for paclitaxel protein bound particles

2017-11-30 thehindubusinessline
Panacea Biotec Ltd has announced that its abbreviated new drug application (ANDA) submitted under section 505(j) of the Federal Food, Drug and Cosmetic Act for paclitaxel protein bound particles for injectable suspension, 100mg/vial has been accepted for filing by the US Food and Drug Administration.

Panacea Biotec Limited - Press Release

2017-11-30 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

Panacea Biotec Limited - Corrigendum

2017-11-22 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information. (15-0)

Panacea Biotec Limited - Press Release

2017-11-15 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information. (15-0)

Market Live: Sensex extends losses, Nifty breaks 10,150; ONGC, Sun Pharma fall 3-4%

2017-11-15 moneycontrol
12:55 pm Market Update: Equity benchmarks extended losses amid volatility, tracking weak global cues after trade deficit data. (15-0)

Panacea Biotec, Cox Kings up 7-8% on strong Q2 numbers

2017-11-15 moneycontrol
Shares of Panacea Biotec and Cox & Kings rose 7-8 percent intraday Wednesday on the back strong September quarter (Q2FY18) numbers.

Market Live: Sensex opens below 33K, Nifty mildly lower; Sun Pharma, Vedanta dip 2%

2017-11-15 moneycontrol
10:32 am Market Check: Benchmark indices as well as broader markets continued to trade mildly lower, weighed by weak global cues. Metals, FMCG, oil & gas exploration and HDFC Group stocks were under pressure. (6-0)

Panacea Biotec Limited - Updates

2017-10-31 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information. (15-0)

Panacea Biotec Limited - Shareholders meeting

2017-10-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information. (15-0)

Panacea Biotec says ANDA of Prasugrel approved by US FDA

2017-10-24 business-standard
Drug firm Panacea Biotec on Tuesday said it has received final approval from the US health regulator to launch generic Prasugrel tablets, used for preventing blood clots in people with acute coronary syndrome, in the American market. The company is also entitled for 180 days of shared market exclusivity for the Prasugrel HCL tablets, it added.